Oncology News | pharmaphorum

News

NICE backs frontline use of Jemperli in endometrial cancer

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 w

News

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan i

News

4SC files maintenance CTCL therapy Kinselby in EU

German biotech 4SC has filed its oral HDAC inhibitor Kinselby with the EMA, hoping to provide a much-needed new therapy for patients with the rare cancer cutaneous T-Cell

News

MHRA okays first drug under new mutual recognition scheme

A new formulation of Amgen’s cancer treatment Xgeva is the first to be approved in the UK under a new procedure designed to speed up access to new therapies.

News

Pfizer’s new cancer unit sees eight new blockbusters by 2030

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest

News

AbbVie inks $713m deal for OSE chronic inflammation drug

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im

NICE backs frontline use of Jemperli in endometrial cancer

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

4SC files maintenance CTCL therapy Kinselby in EU

MHRA okays first drug under new mutual recognition scheme

Pfizer’s new cancer unit sees eight new blockbusters by 2030

AbbVie inks $713m deal for OSE chronic inflammation drug

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks